Wegovy could be offered to cut heart attack and stroke risk
A treatment option – GLP-1 drug semaglutide known as Wegovy – is set to be available on the NHS within months, with 1.2 million people with cardiovascular disease eligible to receive the treatment to help prevent heart attacks and strokes over the next few years. People with heart and circulatory disease who are overweight will be able to receive the drug in England from this summer, following approval by the National Institute for Health and Care Excellence.